News headlines about USANA Health Sciences (NYSE:USNA) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. USANA Health Sciences earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 43.8694563856009 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern’s rankings:

Shares of USANA Health Sciences (NYSE:USNA) opened at $74.30 on Friday. The firm has a market cap of $1,786.24, a P/E ratio of 20.47 and a beta of 1.06. USANA Health Sciences has a one year low of $52.55 and a one year high of $76.15.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.11. The company had revenue of $261.77 million during the quarter, compared to analyst estimates of $259.52 million. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.40 EPS. research analysts predict that USANA Health Sciences will post 3.7 EPS for the current year.

USNA has been the subject of a number of analyst reports. Pivotal Research boosted their target price on shares of USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th. BidaskClub raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th.

In other news, Director Myron W. Wentz sold 164,916 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $66.40, for a total value of $10,950,422.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert A. Fuller sold 1,710 shares of the company’s stock in a transaction that occurred on Thursday, October 26th. The stock was sold at an average price of $67.01, for a total transaction of $114,587.10. Following the completion of the sale, the director now directly owns 1,710 shares of the company’s stock, valued at $114,587.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 623,752 shares of company stock valued at $41,411,372. Company insiders own 53.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/14/usana-health-sciences-usna-earning-somewhat-positive-news-coverage-study-shows.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.